aakash datta
TRANSCRIPT
-
8/8/2019 AAKASH DATTA
1/23
Pharmaceutical industry in India.
yBy-
AAKASH DATTA
S-102
FYBMS.
-
8/8/2019 AAKASH DATTA
2/23
The Indian pharmaceutical industry has
come a long way from waiting for imports
of bulk drugs from global players for re-
processing to becoming an industry whichis driving the product development and is
breaking new grounds in medical research
worldwide.
-
8/8/2019 AAKASH DATTA
3/23
INTRODUCTION
Pharmaceutical Industryin Indiais one ofthelargestand mostadvanced amongthedevelopingcountries.( Itisranked 4thinvolumetermsand 11thin valuetermsglobally.)
Fromsimple pain killersto sophisticatedantibioticsand complexcardiaccompounds,almosteverytype of drugis nowmadeindigenously.(70% ofthecountry's demand met
by Indian pharmaceuticalindustry) industrytraditionallyrelied on reverseengineering
-
8/8/2019 AAKASH DATTA
4/23
INDUSTRY STRUCTURE estimated worth $ 4.5 billion, growing at about 8 to
9 percent annually
over 3,000 small/medium sized genericpharmaceutical manufacturers
The leading 250 pharmaceutical companies control70% of the market (market leader holdingnearly 7% of the market share)
5 Central Public Sector Units that manufacturedrugs
over 60,000 formulations manufactured in India inmore than 60 therapeutic segments
DRUG SYSTEM IN INDIA(Ayurveda, Siddha,Unani, Homeopathy, Naturopathy)
-
8/8/2019 AAKASH DATTA
5/23
Top ten pharmaceutical companies in India
Ranbaxy Laboratories: By sales India's largest pharma firm with the returns touching Rs4,198.96 crore (Rs 41.989 billion) in 2007
Dr Reddy's Laboratories:With a turnover of Rs 4,162.25 crore (Rs 41.622 billion) in2007, Dr Reddy's lab is second largest drug firm in India by sales .
Cipla: Cipla generated an annual revenue of Rs 3,763.72 crore (Rs 37.637 billion) in 2007making itself the third largest pharmaceutical firms.
Sun Pharma Industries: Sun Pharma Industries had an overall earnings of Rs 2,463.59 crore(Rs 24.635 billion) in 2007.
Lupin Labs: Lupin Labs yielded total profit of Rs 2,215.52 crore (Rs 22.155 billion) in 2007.
Aurobindo Pharma: India's sixth largest pharma company by sales, Aurobindo posted Rs2,080.19 crore (Rs 20.801 billion) annual returns in 2007.
GlaxoSmithKline Pharma:With 2007 turnover touching Rs 1,773.41 crore (Rs 17.734billion, GSK is India's seventh largest pharma firm.
Cadila Healthcare: Cadila's earnings was Rs 1,613.00 crore (Rs 16.13 billion) in the fiscalyear 2007, establishing itself as India's eight largest drug company.
Aventis Pharma:With an annual revenue of Rs 983.80 crore (Rs 9.838 billion) in 2007,Aventis Pharma has made a place for itself in the top ten pharma companies in India
Ipca Laboratories: Ipca is India's 10th largest pharma company by sales and in 2007 it had aturnover of Rs 980.44 crore (Rs 9.804 billion)
-
8/8/2019 AAKASH DATTA
6/23
Other pharmaceutical companies in India Baidyanath group
Biocon
Cadila Healthcare
Dabur
Dey's Medical
Hamdard (Wakf)Laboratories
Hetero Drugs
Hindustan Antibiotics Limited
Medisys Biotech
Nectar Lifesciences
y Nicholas Piramal
y Panacea Biotec
y Pharmaceuticals in India
yG. V. Prasad
y RPG Life Sciences
y Serum Institute of India
y Strides Arcolab
y TTK Groupy Torrent Pharmaceuticals
y Wockhardt
-
8/8/2019 AAKASH DATTA
7/23
INDUSTRY SEGMENTATION
Indian pharmaceutical industry can be
widely classified into
y bulk drugs,y formulations and
y contract research
-
8/8/2019 AAKASH DATTA
8/23
DOMESTICEXPORTS
YEAR EXPORT (Rs. in Crores)
1998-1999 6256.06
1999-2000 7230.16
2000-2001 8757.47
2001-2002 9751.20
2002-2003 12826.10
2003-2004 15213.24
2004-2005 17857.80
2005-2006 22578.98
2006-2007 24942.00
Pharmaceutical exports touched a
level of Rs. 24942 crores during
2006-07. The formulations
contribute nearly 55% of the total
exports and the rest 45% comesfrom bulk drugs. Pharmaceutical
exports clocked $7.2 billion in
2007-08, accounting for six per
cent of the countrys total exports,
according toPharmexcil, the Pharmaceutical
Export Promotional Council.(Source:-Directorate General of CommercialIntelligence and Statistics - DGCIS, Kolkata)
-
8/8/2019 AAKASH DATTA
9/23
SWOTANALYSISSTRENGTHS-
1. India with a population of over a billion is a largely untappedmarket.(In fact the penetration of modern medicine is less than 30% inIndia.)
2.Thegrowth of middle class in the country has resulted in fastchanging lifestyles in urban and to some extent rural centres.
3. Indian manufacturers are one of the lowest cost producers of
drugsin the world.
4.Indian pharmaceutical industry possesses excellent chemistryand process reengineering skills.
-
8/8/2019 AAKASH DATTA
10/23
WEAKNESS
y price regulation.
y lack of product patent
y least penetrated in the world.
y Due to very low barriers to entry, Indian
pharma industry is highly fragmented (300large manufacturing units and about 18,000small units spread across the country. )
-
8/8/2019 AAKASH DATTA
11/23
OPPORTUNITIES
The migration into a product patent based regime islikely to transform industry fortunes in the long term.
Large number of drugs going off-patent in Europeand in the US between 2005 to 2009 offers a big
opportunity for the Indian companies to capture thismarket.
Opening up of health insurance sector and theexpected growth in per capita income are key growth
drivers from a long-term perspective. Being the lowest cost producer combined with FDA
approved plants; Indian companies can become aglobal outsourcing hub for pharmaceutical products.
-
8/8/2019 AAKASH DATTA
12/23
THREATS
There are certain concerns over the patent regime regarding its
current structure. It might be possible that the new government
may change certain provisions of the patent act formulated by the
preceding government.
Threats from other low cost countries like China and Israel exist.
However, on the quality front, India is better placed relative to
China. So, differentiation in the contract manufacturing side maywane.
-
8/8/2019 AAKASH DATTA
13/23
PORTERS FIVE FORCES MODEL
-
8/8/2019 AAKASH DATTA
14/23
INDUSTRYCOMPETITION
y 10,000 different players (High growth prospects make itattractive for new players to enter in the industry)
y entry barriers to pharmaceutical industry are very low.
y
small players that are focussed on a particular region have abetter hang of the distribution channel, making it easier to
succeed
-
8/8/2019 AAKASH DATTA
15/23
BARGAININGPOWEROF
BUYERS
unique feature of pharmaceutical industry -end
user of the product is different from the
influencer (read doctor).
In pharmaceutical industry, the buyers arescattered and they as such do not wield much
power in the pricing of the products.
However, govt with its policies, plays an important
role in regulating pricing through the NPPA(national pharmaceutical pricing authority).
-
8/8/2019 AAKASH DATTA
16/23
BARGAINING POWER OF
SUPPLIERS
The suppliers have very low bargaining power and the
companies in the pharmaceutical industry can switch from
their suppliers without incurring a very high cost.
Supplier can go for forward integration to become apharmaceutical company.(companies like Orchid Chemicals
and Sashun Chemicals were basically chemical companies
who turned themselves into pharmaceutical companies.)
-
8/8/2019 AAKASH DATTA
17/23
BARRIERSTOENTRY
The capital requirement for the industry is very low; creating a
regional distribution network is easy, since the point of sales is
restricted in this industry in India.
However, creating brand awareness and franchisee among
doctors is the key for long term survival.
Also, quality regulations by the government may put some
hindrance for establishing new manufacturing operations.
The new patent regime has raised the barriers to entry.
But it is unlikely to discourage new entrants, as market forgenerics will be as huge.
-
8/8/2019 AAKASH DATTA
18/23
THREAT OF SUBSTITUTES
Whatever happens, demand for pharmaceutical productscontinues and the industry thrives.
One of the key reasons for high competitiveness in the industry is
that as an ongoing concern, pharmaceutical industry seems to
have an infinite future. However, in recent times the advances made in thee field of
biotechnology, can prove to be a threat to the synthetic
pharmaceutical industry.
Yoga and neuropathy
-
8/8/2019 AAKASH DATTA
19/23
INDIAN PHARMACEUTICAL SECTOR: FUTURESCENARIO
marking presence globally and competing with thepharmaceutical companies from the developed countries like
Europe, Japan, and United States
generic drug sales to promote drug discovery projects and new
delivery technologies. Contract research in India is also growingat the rate of 20-25% per year and was valued at US$ 10-
120millio
We can expect a significant level of consolidation- a major
portion of small players are likely to be wiped out
-
8/8/2019 AAKASH DATTA
20/23
ISSUES ANDCHALLENGES
y Mergers andAcquisitions
-
8/8/2019 AAKASH DATTA
21/23
y Attracting and retaining a skilled workforce
y Controlling operating costs
y Infrastructure
y Impact of new patent law
-
8/8/2019 AAKASH DATTA
22/23
BIBLIOGRAPHY
www.oppi.com www.capitaline.com www.google.com www.wikipedia.com www.altavista.com
www.site.securities.com www.pharmainfo.com www.etintelligence.com www.pharmainfo.net www.kpmg.de www.info.shine.com www.equitymaster.com www.expresspharmaonline.com
-
8/8/2019 AAKASH DATTA
23/23
THANK
YOU.
AAKASH DATTA
S
-102FYBMS